Abstract: The present invention belongs to the technical field of medicine, and specifically relates to the preparation process of compounds, as represented by formulas (I) and (I?), and intermediates thereof. The preparation process of the present invention has lower production cost and generates less three wastes.

Abstract: The present invention belongs to the technical field of medicine, and relates in particular to a crystal form of a fibroblast growth factor receptor inhibitor shown in formula (I), and a preparation method therefor.

Abstract: The present invention relates to a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. Also provided is a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4±0.2°, 17.9±0.2°, 18.9±0.2°, 19.4±0.2°, 21.5±0.2°, and 23.7±0.2°.

Abstract: The present invention belongs to the technical field of medicines, and particularly relates to a method for synthesizing an anti-tumor compound and intermediates thereof. The synthesis method of the present invention has improved operability and allows for a simplified process, in which higher purity can be achieved without the complicated process of recrystallizing the synthesized target compound, and thus less of the three wastes is produced, making the method more suitable for industrial mass production. Where the intermediates according to the present invention are used for preparing an anti-tumor compound, by-products are effectively reduced during reactions, and thus the overall yield of the reactions are improved, and is at least twice as high as that obtained using the existing synthesis method.

Abstract: The present invention belongs to the technical field of medicines, relates to novel use of a multi-kinase inhibitor, and particularly relates to a compound of general formula (I) or a pharmaceutically acceptable salt, a stereoisomer and a crystal form thereof for use in the treatment of biliary tract cancer, a pharmaceutical composition comprising the compound, a method for treating biliary tract cancer by using the compound, use of the compound in the treatment of biliary tract cancer, and use of the compound in the preparation of a medicament for treating biliary tract cancer. The variables in the general formula are defined in the specification. Research shows that the multi-kinase inhibitor compound of general formula (I) or the pharmaceutically acceptable salt, the stereoisomer and the crystal form thereof have a treatment effect on biliary tract cancer, and especially on cholangiocarcinoma, so that the compound of the present invention has huge clinical application potential.

Abstract: The present invention falls within the technical field of medicine, and in particular relates to a crystal form of a phosphodiesterase inhibitor as shown in formula (I), a preparation method therefor and the use thereof.

Abstract: The present invention relates to a compound of formula I or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an ester, an optical isomer or a prodrug thereof, a pharmaceutical composition comprising the compound of formula I, and use of the compound, as a Bruton's tyrosine kinase inhibitor with high selectivity for BTK(C481S) mutant, in the manufacture of a medicament for preventing or treating a heteroimmune disease, an autoimmune disease or a cancer.

Abstract: The present invention falls within the technical field of medicine, and in particular relates to a crystal form of a phosphodiesterase inhibitor as shown in formula (I), a preparation method therefor and the use thereof.

Abstract: Disclosed are uses of a compound represented by general formula (I) and pharmaceutically acceptable salts, isomers and deuterated compounds thereof in the preparation of a medicine for treating heart failure diseases. Experiments prove that the compound can improve the heart function of rats with heart failure, reverse myocardial remodeling caused by heart failure, and reduce fibrosis in the marginal zone of infarction.

Abstract: The present invention relates to the technical field of pharmaceuticals. Specifically, the present invention relates to a halo-allylamine compound, or a pharmaceutically acceptable salt, an ester, a stereoisomer or a tautomer thereof, and a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, and use in preventing and/or treating a disease related to or mediated by the SSAO/VAP-1 protein, wherein R1, R2, R3, R4, R5, R6, L1 and Cy1 are defined in the specification.